IMUX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 20.43%, SMA50 38.27%, SMA200 19.33%). The stock’s 14-day RSI is 64.8 (firm momentum), while the ATR of 0.09 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -29.8% below its high and over 87.22% above its low. Average 10-day trading volume of 378.27 thousand shares is below the 3-month average of 428.56 thousand, indicating normal recent market interest.

Immunic, Inc. has 98.65 million shares outstanding. The public float is 65.25 million shares, elevated short interest at 10.10% of float. This equals 9.78 million shares. The short ratio is 8.91 days. Institutional investors hold 56.21% of the float. Insiders own 1.02%. Muehler Andreas holds 297.99 thousand shares, Groeppel Manfred has 278.83 thousand shares and Rudick Richard Alan has 230.38 thousand shares.

Immunic, Inc. generated EPS of -$0.87 over the past year. Five-year average earnings growth is 26.01%. Wall Street analysts project EPS growth of 29.25% annually over the next five years. The latest quarter delivered EPS of -$1.20. The next quarter is forecast at -$0.09. Next year's EPS is expected at $14.90. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $2.50. The high target offers 99.64% upside. The low target suggests -77.31% downside. The mean target is $8.75. This offers -20.6% upside. Immunic, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended February 26, 2026, missed forecasts by 1050.64%. The prior quarter beat by -26.71%. Over the last six quarters, Apple has recorded several small beats. These include 13.64% in March 27, 2025.

Immunic, Inc. (NASDAQ:IMUX) closed at $11.02 USD, losing -$0.26 (-2.30%) from the previous close of $11.28. The stock is currently mid-range between its 52-week high and low $5.06 and $15.10. With a market capitalization of about $108.75 million, Immunic, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.21). Key stats such as the average daily volume over the past year has been around 422.92 thousand shares, in line with its 52-week average. Headquartered in New York City, NY, Immunic, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel Vitt, the company employs approximately 91 people and listed since April 17, 2014. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.

Immunic, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.95. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Immunic, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.26%, with price expected at $10.33 by May 20, 2026, within a range of $9.26 to $11.56 3-Month Outlook: Projected fall of -2.45%, reaching $10.75 by August 04, 2026, with a range of $10.01 to $11.58. 1-Year Outlook: Projected gain of 194.65%, with price at $32.47 by May 06, 2027, within a range of $21.55 to $46.45.

Immunic, Inc. (NASDAQ:IMUX) shares are up 20.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Immunic, Inc. trading at a premium to the broader market with a P/E of -1.73. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.89, suggesting 89.56% upside. Our AI forecast model points to short-term weakness (-6.26% over two weeks), a medium-term fall (-2.45% over three months), and a longer-term gain (194.65% over one year), with expected trading ranges indicating moderate volatility.

Immunic, Inc. trades at a P/E ratio of -1.73, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -25.15 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.24, also below market averages.